Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulfasalazine + fruquintinib + sintilimab for third-line or later pMMR/MSS colorectal cancer
ChiCTR2600116822Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminosalicylic acid + sulphasalazine, fruquintinib and sintilimab in colorectal adenocarcinoma, sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoint: Objective response rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
5-aminosalicylic acid + sulphasalazinefruquintinibsintilimab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600116822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116822.